Floatz logo

Calaspargase Pegol

Aggressive NK-Cell Leukemia

New York Medical Collegeprotein_peptideEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Aggressive NK-Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The Affiliated Hospital of Xuzhou Medical University
Phase 2B
Thiotepa
St. Jude Children's Research Hospital
Phase 2CCC
Anti-Thymoglobulin, Rabbit
St. Jude Children's Research Hospital
Phase 2CCC
Blinatumomab
St. Jude Children's Research Hospital
Phase 2CCC
Evomela
St. Jude Children's Research Hospital
Phase 2CCC

View all 20 →

Same molecule, other indications

Calaspargase Pegol is also rated in:

lymphoblastic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Non-Small-Cell Lung (NSCLC)Dormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →